Remote monitoring device approved for heart patients

May 29, 2014

(HealthDay)—An implanted wireless device that measures key vital signs in people with heart failure has been approved by the U.S. Food and Drug Administration.

The CardioMEMSHF system measures pulmonary artery pressure and and sends this information remotely to the patient's doctors, the FDA said Wednesday in a news release.

The device is intended for people with New York Heart Association Class III , the FDA said. Some 5.8 million people in the United States have heart failure, in which the heart can't pump enough blood. People with NYHA Class III heart failure have difficulty performing everyday tasks such as walking short distances, the agency said.

The device was evaluated in a clinical study involving 550 people. All devices implanted were still working after six months, the FDA said.

The agency said it is requiring a post-approval study to gather information about the device's long-term performance.

The system is manufactured by CardioMEMS Inc., based in Atlanta.

Explore further: FDA OKs HeartWare device for transplant patients

More information: Visit the FDA to learn more about this approval.

Related Stories

FDA approves expanded indication for CRT devices

April 15, 2014

(HealthDay)—The U.S. Food and Drug Administration has approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers (CRT-P) and eight cardiac resynchronization defibrillators (CRT-D). ...

Daily aspirin regimen not safe for everyone, FDA warns

May 6, 2014

(HealthDay)—Taking an aspirin a day can help prevent heart attack and stroke in people who have suffered such health crises in the past, but not in people who have never had heart problems, according to the U.S. Food and ...

Recommended for you

No new heart muscle cells in mice after the newborn period

November 5, 2015

A new study from Sweden's Karolinska Institutet shows that new heart muscle cells in mice are mainly formed directly after birth. After the neonatal period the number of heart muscle cells does not change, and A new study ...

Nanotechnology could spur new heart treatment

October 29, 2015

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.